Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Hydroxychloroquine was granted FDA approval on 18 April 1955.
A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Target Recruit Count
- 63
- Registration Number
- NCT03754179
- Locations
- 🇧🇪
UZ Brussel, Jette, Brabant, Belgium
Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine
- Conditions
- Interventions
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT03687905
- Locations
- 🇪🇬
Fatma Gheet, Tanta, Egypt
Immunosuppressant Regimens for Living Fetuses Study
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 420
- Registration Number
- NCT03671174
- Locations
- 🇨🇳
Renji Hospital, Shanghai, Shanghai, China
Management of Cardiovascular Disease in Kidney Disease (MaCK) Study
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 100
- Registration Number
- NCT03636152
- Locations
- 🇺🇸
North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT03598595
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 300
- Registration Number
- NCT03540810
- Locations
- 🇫🇷
University Hospital Angers, Angers, France
Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-01
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- St Vincent's Hospital, Sydney
- Target Recruit Count
- 12
- Registration Number
- NCT03513211
- Locations
- 🇦🇺
St Vincent's Hospital, Darlinghurst, New South Wales, Australia
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT03449758
- Locations
- 🇫🇷
Investigational Site Number 250014, Caen, France
🇫🇷Investigational Site Number 250006, Besancon, France
🇫🇷Investigational Site Number 250016, Bordeaux, France
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2024-04-09
- Target Recruit Count
- 273
- Registration Number
- NCT03428945
- Locations
- 🇸🇪
Skane University Hospital, Malmö, Sweden
🇺🇸Joslin Center at SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸Endocrinology Specialist / Greenville Health System, Greenville, South Carolina, United States
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 400
- Registration Number
- NCT03414502
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.